文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

局部前列腺癌短期雄激素剥夺治疗与放疗序贯策略的患者报告结局:3期随机对照试验

Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-01-30

OTT-0101研究比较新辅助同期与同期辅助ADT联合前列腺放疗对HR-QoL的影响。两组泌尿、肠道症状及性活动无显著差异;

要点

  • 两组5年泌尿、肠道症状及性活动无 definitive 恶化率无显著差异。
  • 性功能平均评分差异小至中等,临床意义不明确。

核心结论

  • 辅助与 New adjvant 序贯策略在泌尿、肠道症状及性活动方面无显著差异。
  • 辅助ADT与性功能 definitive 恶化风险降低相关,但平均评分差异小至中等,结论不明确。

研究设计与样本

  • 3期随机对照试验OTT-0101,纳入Gleason评分≤7、临床分期T1b-T3a、PSA<30 ng/mL的前列腺癌患者。
  • 随机分为新辅助同期ADT6个月(放疗前4个月开始)或同期辅助ADT6个月(与放疗同时开始)。
  • HR-QoL采用EORTC QoL问卷评估,主要分析至 definitive 恶化的时间。

主要发现

  • 共393例可评估(新辅助组194例,辅助组199例),其中性功能可评估214例(101例和113例)。
  • 5年泌尿症状无 definitive 恶化率:新辅助组33.5%,辅助组34.1%,无显著差异。
  • 5年肠道症状无 definitive 恶化率:新辅助组33.1%,辅助组35.4%,无显著差异。
  • 5年性活动无 definitive 恶化率:新辅助组38.5%,辅助组36.7%,无显著差异。

关键数值与推荐

  • 5年泌尿症状无 definitive 恶化率:新辅助组33.5%,辅助组34.1%。
  • 5年肠道症状无 definitive 恶化率:新辅助组33.1%,辅助组35.4%。
  • 5年性活动无 definitive 恶化率:新辅助组38.5%,辅助组36.7%。

临床怎么用

  • 两种序贯策略对泌尿、肠道症状及性活动的影响无显著差异,临床选择时可综合考虑。
  • 辅助ADT可能降低性功能 definitive 恶化风险,但差异临床意义不明确,需个体化沟通。

局限性

  • 可能存在I类和II类错误。
  • 平均评分变化缺乏持续且临床有意义的组间差异,性功能影响结论不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Two phase 3 randomized controlled trials (OTT-0101, RTOG-9413) and a meta-analysis have shown an impact of sequencing of androgen deprivation therapy (ADT) and radiation therapy on oncologic outcomes in prostate cancer (PCa). However, the impact of sequencing strategy on health-related quality of life (HR-QoL) is unclear. Here, we present the patient-reported HR-QoL outcomes from the OTT-0101 study. METHODS AND MATERIALS: In this trial, patients with PCa with Gleason score ≤7, clinical stage T1b to T3a, and prostate-specific antigen level <30 ng/mL were randomly assigned to neoadjuvant and concurrent ADT for 6 months, starting 4 months before or concurrent with prostate radiation therapy, or concurrent and adjuvant ADT for 6 months, starting simultaneously with prostate radiation therapy. HR-QoL was assessed using European Organisation for Research and Treatment of Cancer QoL questionnaires. Time until definitive deterioration was defined as time from random allocation to the first deterioration of at least 10 points with no further improvement of ≥10 points or if the patient experienced progression, died, or dropped out after deterioration, resulting in missing data. Stratified log-rank tests were applied for between-group comparisons of time-to-event estimates. RESULTS: Overall, 393 patients (194 and 199 in the 2 arms, respectively) were evaluable, except 214 (101 and 113 in the 2 arms, respectively) for sexual function. Five-year rates of freedom from definitive deterioration of urinary symptoms, bowel symptoms, and sexual activity were 33.5%, 33.1%, and 38.5% in the neoadjuvant group and 34.1%, 35.4%, and 36.7% in the adjuvant group, respectively, with no significant between-group differences. The adjuvant approach was associated with a reduced risk of definitive deterioration of sexual function (hazard ratio, 0.68; 95% confidence interval, 0.49-0.94; P = .02). With respect to clinical relevance, the mean change in score for sexual function showed only a small to moderate difference favoring the adjuvant group at and beyond 3 years. CONCLUSIONS: In this study, no differences were found in the bowel or urinary symptoms between the adjuvant and neoadjuvant approach. Considering a significant likelihood of type I and type II errors and because of a lack of a persistent and clinically meaningful between-group difference in mean score changes over time, our findings do not confer a clear and conclusive picture of the impact of sequencing strategy on sexual function.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Roy S, Grimes S, Morgan SC, et al. Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33524545. doi:10.1016/j.ijrobp.2021.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。